Alberto Hernando-Calvo, Clinician scientist at Vall d’Hebron Barcelona Hospital, shared a post on LinkedIn:
“Just out! Clinical trial protocol publication of the Beamion PANTUMOR-1, basket study of Zongertinib for patients with advanced solid tumors and different HER2 aberrations.
Very proud to work with outstanding investigators all over the globe.”
Title: Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors
Authors: Alison M. Schram, John J. Park, Antoine Italiano, Shigehisa Kitano, Ye Guo, Jin Li, Philippe L. Bedard, Cedric van Marcke, Ryo Ko, Lukas Lunger, Daniel M. Klotz, Jo Hussain, Daniela Maier, Damijan Erzen, David Planchard, Hans Prenen, Timothy D. Clay, Joon O. Park, Hyung-Don Kim, Alberto Hernando-Calvo, Yuta Maruki, Mariano Ponz-Sarvise, Ecaterina Dumbrava
Read The Full Article
Other articles about Beamion PANTUMOR-1 on OncoDaily.